Home › Companies › Arcus Biosciences, Inc. › 2024-2025
Compiled from SEC Form N-PX filings and Arcus Biosciences, Inc.’s Form 8-K, filed 2025-06-12 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Arcus Biosciences, Inc. in the interactive database Compare manager voting policies
These tallies are Arcus Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-12 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Yasunori Kaneko, M.D. | 86,171,508 | -- | -- | 4,142,191 | 8,580,999 | Majority: yes |
| Elect Director: Patrick Machado, J.D. | 72,358,392 | -- | -- | 17,955,307 | 8,580,999 | Majority: yes |
| Elect Director: Andrew Perlman, M.D., Ph.D | 84,672,810 | -- | -- | 5,640,889 | 8,580,999 | Majority: yes |
| Elect Director: Antoni Ribas, M.D., Ph.D. | 74,827,393 | -- | -- | 15,486,306 | 8,580,999 | Majority: yes |
| Proposal 2: The ratification of the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025: | 96,750,327 | 1,952,359 | 192,012 | -- | -- | Majority: yes |
| Proposal 3: The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement: | 84,812,809 | 5,446,383 | 54,507 | -- | 8,580,999 | Majority: yes |
Source: Arcus Biosciences, Inc., Form 8-K, filed with the SEC on 2025-06-12 — read the filing on EDGAR.
Each item below shows how the 211 asset managers that disclosed a Arcus Biosciences, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Arcus Biosciences, Inc.’s own tally for this item (“Proposal 3: The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement:”): 84,812,809 for, 5,446,383 against, per its Form 8-K filed 2025-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,900,000 outstanding shares: 80% for, 5% against (85% of the company cast a for/against vote).
The 210 asset managers below cast 96% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 31,424,760 | 0 | 0 | 0 | For |
| Fidelity | 10,104,138 | 0 | 0 | 0 | For |
| BlackRock | 8,795,695 | 14,443 | 0 | 0 | For |
| Vanguard | 6,744,725 | 3,849 | 0 | 0 | For |
| Woodline Partners LP | 6,292,618 | 0 | 0 | 0 | For |
| State Street | 3,718,420 | 23,471 | 0 | 0 | For |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 3,398,503 | 0 | 0 | 0 | For |
| Point72 | 2,081,016 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 0 | 0 | 0 | 0 | Unvoted |
| GEODE CAPITAL MANAGEMENT, LLC | 1,409,668 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 1,396,275 | 0 | 0 | Against |
| Charles Schwab | 1,392,716 | 0 | 0 | 0 | For |
| Dimensional | 1,212,487 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 1,029,400 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 744,301 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 627,626 | 0 | 0 | 0 | For |
| Sofinnova Investments, Inc. | 503,101 | 0 | 0 | 0 | For |
| Wellington | 472,544 | 0 | 0 | 0 | For |
| Northern Trust | 407,187 | 459 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 384,924 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 379,100 | 0 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 379,100 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 336,085 | 0 | 0 | 0 | For |
| Granahan Investment Management, LLC | 308,320 | 0 | 0 | 0 | For |
| NORDEA INVESTMENT MANAGEMENT AB | 0 | 281,869 | 0 | 0 | Against |
Showing the 25 largest of 210 asset managers. See all 210 in the interactive database.
Combines 3 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Andrew Perlman, M.D., Ph.D”): 84,672,810 for, 5,640,889 withheld, per its Form 8-K filed 2025-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,900,000 outstanding shares: 80% for, 5% withheld (85% of the company cast a for/withheld vote).
The 71 asset managers below cast 100% of the shares they voted on this item FOR (23,481,581 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 6,842,859 | 0 | 0 | 0 | For |
| Vanguard | 6,561,971 | 0 | 11 | 0 | For |
| Fidelity | 5,682,656 | 0 | 0 | 0 | For |
| State Street | 1,275,371 | 0 | 527 | 0 | For |
| Dimensional | 0 | 0 | 993,030 | 0 | Abstain |
| Charles Schwab | 651,485 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 379,100 | 0 | 0 | 0 | For |
| Victory Capital | 169,107 | 0 | 0 | 0 | For |
| Equitable | 88,160 | 0 | 58,500 | 0 | For |
| Columbia Threadneedle | 142,961 | 0 | 0 | 0 | For |
| Jackson National | 115,043 | 0 | 20,859 | 0 | For |
| TIAA | 129,930 | 0 | 0 | 0 | For |
| American Century | 105,381 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 95,512 | 0 | 0 | 0 | For |
| MFS | 78,952 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 77,040 | 0 | 0 | 0 | For |
| Prudential/PGIM | 60,673 | 0 | 14,180 | 0 | For |
| BNY Mellon | 71,161 | 0 | 0 | 0 | For |
| Principal | 65,361 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 59,317 | 0 | 0 | 0 | For |
| Empower | 53,707 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 49,977 | 0 | 0 | 0 | For |
| Thrivent | 49,429 | 0 | 0 | 0 | For |
| Lincoln Financial | 40,300 | 0 | 7,101 | 0 | For |
| Goldman Sachs | 46,686 | 0 | 0 | 0 | For |
Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.
Combines 3 wordings of this item as funds reported it.
83% Majority: yes · of votes cast
Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Antoni Ribas, M.D., Ph.D.”): 74,827,393 for, 15,486,306 withheld, per its Form 8-K filed 2025-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,900,000 outstanding shares: 71% for, 15% withheld (85% of the company cast a for/withheld vote).
The 71 asset managers below cast 100% of the shares they voted on this item FOR (20,707,914 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 6,842,859 | 0 | 0 | 0 | For |
| Vanguard | 6,561,961 | 0 | 21 | 0 | For |
| Fidelity | 5,677,425 | 0 | 5,231 | 0 | For |
| State Street | 3,309 | 0 | 1,272,589 | 0 | Abstain |
| Dimensional | 0 | 0 | 993,030 | 0 | Abstain |
| Charles Schwab | 651,485 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 379,100 | 0 | Abstain |
| Victory Capital | 0 | 0 | 169,107 | 0 | Abstain |
| Equitable | 88,160 | 0 | 58,500 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 142,961 | 0 | Abstain |
| Jackson National | 115,043 | 0 | 20,859 | 0 | For |
| TIAA | 129,930 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 105,381 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 95,512 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 78,952 | 0 | Abstain |
| ALPS ETF Trust | 0 | 0 | 77,040 | 0 | Abstain |
| Prudential/PGIM | 60,673 | 0 | 14,180 | 0 | For |
| BNY Mellon | 71,161 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 65,361 | 0 | Abstain |
| Direxion Shares ETF Trust | 0 | 0 | 59,317 | 0 | Abstain |
| Empower | 0 | 0 | 53,707 | 0 | Abstain |
| Exchange Place Advisors Trust | 49,977 | 0 | 0 | 0 | For |
| Thrivent | 0 | 0 | 49,429 | 0 | Abstain |
| Lincoln Financial | 0 | 0 | 47,401 | 0 | Abstain |
| Goldman Sachs | 46,686 | 0 | 0 | 0 | For |
Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.
Combines 3 wordings of this item as funds reported it.
80% Majority: yes · of votes cast
Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Patrick Machado, J.D.”): 72,358,392 for, 17,955,307 withheld, per its Form 8-K filed 2025-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,900,000 outstanding shares: 68% for, 17% withheld (85% of the company cast a for/withheld vote).
The 71 asset managers below cast 100% of the shares they voted on this item FOR (20,023,416 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 6,436,892 | 0 | 405,967 | 0 | For |
| Vanguard | 6,558,120 | 0 | 3,862 | 0 | For |
| Fidelity | 5,667,675 | 0 | 14,981 | 0 | For |
| State Street | 3,309 | 0 | 1,272,589 | 0 | Abstain |
| Dimensional | 0 | 0 | 993,030 | 0 | Abstain |
| Charles Schwab | 651,485 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 379,100 | 0 | Abstain |
| Victory Capital | 0 | 0 | 169,107 | 0 | Abstain |
| Equitable | 88,160 | 0 | 58,500 | 0 | For |
| Columbia Threadneedle | 142,961 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 135,902 | 0 | Abstain |
| TIAA | 129,930 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 105,381 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 95,512 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 78,952 | 0 | Abstain |
| ALPS ETF Trust | 0 | 0 | 77,040 | 0 | Abstain |
| Prudential/PGIM | 60,673 | 0 | 14,180 | 0 | For |
| BNY Mellon | 0 | 0 | 71,161 | 0 | Abstain |
| Principal | 0 | 0 | 65,361 | 0 | Abstain |
| Direxion Shares ETF Trust | 0 | 0 | 59,317 | 0 | Abstain |
| Empower | 0 | 0 | 53,707 | 0 | Abstain |
| Exchange Place Advisors Trust | 49,977 | 0 | 0 | 0 | For |
| Thrivent | 0 | 0 | 49,429 | 0 | Abstain |
| Lincoln Financial | 0 | 0 | 47,401 | 0 | Abstain |
| Goldman Sachs | 0 | 0 | 46,686 | 0 | Abstain |
Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.
Combines 3 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Yasunori Kaneko, M.D.”): 86,171,508 for, 4,142,191 withheld, per its Form 8-K filed 2025-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,900,000 outstanding shares: 81% for, 4% withheld (85% of the company cast a for/withheld vote).
The 71 asset managers below cast 100% of the shares they voted on this item FOR (23,481,221 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 6,842,859 | 0 | 0 | 0 | For |
| Vanguard | 6,561,975 | 0 | 7 | 0 | For |
| Fidelity | 5,682,656 | 0 | 0 | 0 | For |
| State Street | 1,275,371 | 0 | 527 | 0 | For |
| Dimensional | 0 | 0 | 993,030 | 0 | Abstain |
| Charles Schwab | 651,485 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 379,100 | 0 | 0 | 0 | For |
| Victory Capital | 169,107 | 0 | 0 | 0 | For |
| Equitable | 88,160 | 0 | 58,500 | 0 | For |
| Columbia Threadneedle | 142,961 | 0 | 0 | 0 | For |
| Jackson National | 115,043 | 0 | 20,859 | 0 | For |
| TIAA | 129,930 | 0 | 0 | 0 | For |
| American Century | 105,381 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 95,512 | 0 | 0 | 0 | For |
| MFS | 78,952 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 77,040 | 0 | 0 | 0 | For |
| Prudential/PGIM | 60,673 | 0 | 14,180 | 0 | For |
| BNY Mellon | 71,161 | 0 | 0 | 0 | For |
| Principal | 65,361 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 59,317 | 0 | 0 | 0 | For |
| Empower | 53,707 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 49,977 | 0 | 0 | 0 | For |
| Thrivent | 49,429 | 0 | 0 | 0 | For |
| Lincoln Financial | 40,300 | 0 | 7,101 | 0 | For |
| Goldman Sachs | 46,686 | 0 | 0 | 0 | For |
Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.
Combines 2 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Arcus Biosciences, Inc.’s own tally for this item (“Proposal 2: The ratification of the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending”): 96,750,327 for, 1,952,359 against, per its Form 8-K filed 2025-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,900,000 outstanding shares: 91% for, 2% against (93% of the company cast a for/against vote).
The 71 asset managers below cast 97% of the shares they voted on this item FOR (23,819,064 for, 812,026 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 6,842,859 | 0 | 0 | 0 | For |
| Vanguard | 6,558,140 | 3,842 | 0 | 0 | For |
| Fidelity | 5,682,656 | 0 | 0 | 0 | For |
| State Street | 1,275,813 | 85 | 0 | 0 | For |
| Dimensional | 993,030 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 651,485 | 0 | 0 | Against |
| Delaware/Macquarie | 379,100 | 0 | 0 | 0 | For |
| Victory Capital | 169,107 | 0 | 0 | 0 | For |
| Equitable | 146,660 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 142,961 | 0 | 0 | 0 | For |
| Jackson National | 135,902 | 0 | 0 | 0 | For |
| TIAA | 129,930 | 0 | 0 | 0 | For |
| American Century | 105,381 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 95,512 | 0 | 0 | 0 | For |
| MFS | 78,952 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 77,040 | 0 | 0 | 0 | For |
| Prudential/PGIM | 74,853 | 0 | 0 | 0 | For |
| BNY Mellon | 71,161 | 0 | 0 | 0 | For |
| Principal | 65,361 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 59,317 | 0 | 0 | 0 | For |
| Empower | 53,707 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 0 | 49,977 | 0 | 0 | Against |
| Thrivent | 49,429 | 0 | 0 | 0 | For |
| Lincoln Financial | 47,401 | 0 | 0 | 0 | For |
| Goldman Sachs | 46,686 | 0 | 0 | 0 | For |
Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.
Ranked by the number of Arcus Biosciences, Inc. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 105,900,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | GILEAD SCIENCES, INC. | 29.67% |
| 2 | Fidelity | 9.54% |
| 3 | BlackRock | 8.32% |
| 4 | Vanguard | 6.37% |
| 5 | Woodline Partners LP | 5.94% |
| 6 | State Street | 3.53% |
| 7 | SUVRETTA CAPITAL MANAGEMENT, LLC | 3.21% |
| 8 | Point72 | 1.97% |
| 9 | Siren, L.L.C. | 1.52% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1.33% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| GILEAD SCIENCES, INC. | 29.67% | 13D |
| BlackRock, Inc. | 12.03% | 13G |
| The Vanguard Group, Inc. | 5.82% | DEF14A |
| FMR (Fidelity) | 4.21% | 13F |
| State Street | 3.49% | 13F |
| Terry Rosen, Ph.D. | 2.43% | DEF14A |
| Dimensional Fund Advisors | 1.63% | 13F |
| Juan Carlos Jaen, Ph.D. | 1.36% | DEF14A |
| Geode Capital | 1.31% | 13F |
| Wellington Management | 1.02% | 13F |
Percentages above are of 105,900,000 shares outstanding, as reported by Arcus Biosciences, Inc. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Arcus Biosciences, Inc.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Arcus Biosciences, Inc.'s shareholder meeting held 2025-06-10, in the 2024-2025 proxy season, 211 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 1,623 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE… — FOR was 94% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Arcus Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-12.
Arcus Biosciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.